Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05260684 · ClinicalTrials.gov registry record
Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 716
- Enrollment target
NCT05260684: Completed study, sponsored by Pfizer.
NCT05260684 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 716 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05260684 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 716 participants
- Enrollment target
Study Summary
This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy. The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
Primary Outcome
As per COLUMBUS trial, OS was defined as the time from the date of randomization to the date of death due to any cause; if death was not observed, participants were censored at the date of last contact or the data analysis cut-off date, whichever occurred first. As per Flatiron EHR, OS was defined as the time from the index date to the date of death; participants without a date of death were censored at their last known activity date or the end of the follow-up period, whichever occurred first.
Interventions
- DRUG Vemurafenib
- DRUG Binimetinib
- DRUG Cobimetinib
- DRUG Dabrafenib
- DRUG Encorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 716 participants |
| Start Date | 2022-01-17 |
| Est. Completion | 2023-12-31 |
What the finished NCT05260684 record still lists
NCT05260684 is an observational study that tracks outcomes without assigning an intervention. The registered 716 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 5 interventions - of which Vemurafenib is the first listed.
NCT05260684 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05260684 about?
NCT05260684 is a clinical study titled "Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US". This study aims to compare real-world effectiveness of BRAF/MEK inhibitors in BRAF-mutant metastatic melanoma patients in the United States by line of therapy. The Flatiron Health electronic health record (EHR) data from US cancer clinics will be used for this retrospective database analysis.
What is the current status of trial NCT05260684?
This trial is currently completed. The enrollment target is 716 participants. The study started on 2022-01-17. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT05260684?
The interventions under investigation include: Vemurafenib (DRUG), Binimetinib (DRUG), Cobimetinib (DRUG), Dabrafenib (DRUG), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT05260684?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04680000 · 716 participants · NA
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
- NCT05208762 · 714 participants · Phase 1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- NCT06758401 · 714 participants · Phase 3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- NCT04916327 · 720 participants · NA
Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI